Patients less that 2 months after the first hemorrhagic or ischemic stroke.
Conditions
Interventions
Product Name: Ritalin
Pharmaceutical Form: Tablet
Concentration unit: g gram(s)
Concentration type: equal
Concentration number: 0,020-
Pharmaceutical form of the placebo: Tablet
Route of administratio
Sponsors
Hammel neurocenter
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Less than two months after first ischemic or hemorrhagic stroke. 2. Moderate to light hand paralysis 3. Able to read and understand the written information 4. Signed informed consend Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Epilepsy 2. Glausoma 3. Hyperthyroidisme 4. Cardiac arytmia 5. Known heart disease or angina. 6. Metal implants 7. Pacemaker 8. Pregnancy 9. Diastolic BP>100 mmHg 10. In treatment with MAO-inhibitor, SSRIs og Ritalin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Measure the effect of Ritalin on short term plasticity in patients with stroke compared to healthy controls. With transcranial magnetic stimulation before and after a trainsession the changes in cortical excitability will be measured.;Secondary Objective: ;Primary end point(s): Changes in Motor Evoked Potentials (MEP), Intra Cortical Inhibition (ICI) and Intra Cortical Fascilitation (ICF). | — |
Countries
Denmark
Outcome results
None listed